US Stock MarketDetailed Quotes
ARDS Aridis Pharmaceuticals
- 0.065
- 0.0000.00%
15min DelayClose Apr 26 15:33 ET
2.90MMarket Cap-406P/E (TTM)
0.065High0.058Low24.36KVolume0.063Open0.065Pre Close1.50KTurnover0.06%Turnover RatioLossP/E (Static)44.57MShares0.54052wk High-0.25P/B2.47MFloat Cap0.05052wk Low--Dividend TTM37.96MShs Float13.850Historical High--Div YieldTTM10.69%Amplitude0.050Historical Low0.061Avg Price1Lot Size
Aridis Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 76.95%-983K | 29.26%-4.34M | 60.63%-4M | -26.99%-29.13M | -129.47%-8.56M | 50.37%-4.27M | 7.08%-6.14M | -153.71%-10.17M | -12.01%-22.94M | 26.81%-3.73M |
| Net income from continuing operations | 98.99%-83K | 252.20%12.14M | 12.23%-6.82M | 28.02%-30.37M | 27.50%-6.39M | 60.77%-8.24M | -45.34%-7.98M | -12.70%-7.77M | -88.93%-42.19M | -51.30%-8.81M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -8,122.22%-722K | --0 |
| Depreciation and amortization | -52.80%59K | -51.91%63K | -33.59%87K | 11.95%487K | -36.31%100K | 32.98%125K | 40.86%131K | 43.96%131K | 29.08%435K | 84.71%157K |
| Other non cash items | -17.86%676K | -75.00%69K | 65.30%605K | -94.83%350K | -493.99%-1.12M | -87.26%823K | --276K | 1,009.09%366K | --6.78M | --283K |
| Change In working capital | -168.55%-1.84M | -1,695.17%-16.83M | 155.80%1.88M | -112.35%-1.3M | -140.76%-1.67M | -49.25%2.68M | 201.34%1.06M | -253.40%-3.36M | 1,804.54%10.52M | 5,211.69%4.09M |
| -Change in receivables | -122.00%-295K | 2,292.94%1.86M | 189.98%1.14M | -865.65%-1M | -224.62%-992K | 223.48%1.34M | -123.74%-85K | -2,111.11%-1.27M | 120.73%131K | 295.58%796K |
| -Change in prepaid assets | 100.74%7K | -161.49%-404K | 19.21%180K | 19.10%212K | 98.84%344K | -189.35%-940K | 161.29%657K | 504.00%151K | -77.97%178K | 63.21%173K |
| -Change in payables and accrued expense | -160.80%-1.61M | 50.64%1.18M | 171.66%1.66M | -96.76%259K | -145.61%-852K | -45.27%2.64M | 365.99%782K | -243.99%-2.31M | 1,053.87%8M | 518.54%1.87M |
| -Change in other current assets | 85.71%78K | --0 | --0 | 85.71%104K | 1.79%57K | --42K | --0 | --5K | 21.74%56K | -26.32%56K |
| -Change in other current liabilities | -150.00%-20K | -216.67%-19K | -240.00%-17K | ---30K | ---11K | ---8K | ---6K | ---5K | --0 | --0 |
| -Change in other working capital | --0 | -6,537.54%-19.45M | -1,817.46%-1.08M | -139.13%-841K | -117.79%-213K | -182.06%-398K | -787.88%-293K | -87.40%63K | --2.15M | --1.2M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 76.95%-983K | 29.26%-4.34M | 60.63%-4M | -26.99%-29.13M | -129.47%-8.56M | 50.37%-4.27M | 7.08%-6.14M | -153.71%-10.17M | -12.01%-22.94M | 26.81%-3.73M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 216.67%14K | 0 | 84.53%-82K | -213.95%-49K | 0 | 90.32%-12K | 93.73%-21K | -44.41%-530K | 112.87%43K |
| Net PPE purchase and sale | --0 | 216.67%14K | --0 | 84.53%-82K | -213.95%-49K | --0 | 90.32%-12K | 93.73%-21K | -44.41%-530K | 112.87%43K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 216.67%14K | --0 | 84.53%-82K | -213.95%-49K | --0 | 90.32%-12K | 93.73%-21K | -44.41%-530K | 112.87%43K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 280.32%999K | 2,278.42%3.03M | -94.08%263K | -57.43%14.78M | 122.82%11.03M | -102.37%-554K | 6.71%-139K | -32.50%4.44M | 300.09%34.72M | -37.72%4.95M |
| Net issuance payments of debt | -63.33%-735K | --3.24M | -129.70%-1.49M | -36.00%3.2M | -127.00%-1.35M | ---450K | --0 | --5M | 599.30%5M | --5M |
| Net common stock issuance | --1.74M | --1K | --2.06M | -57.57%12.61M | 25,832.65%12.61M | --0 | --0 | --0 | 273.82%29.72M | -100.62%-49K |
| Proceeds from stock option exercised by employees | ---- | --0 | --3K | -40.00%3K | ---- | ---- | --0 | --0 | -64.29%5K | --0 |
| Net other financing activities | --0 | -49.64%-208K | 44.17%-311K | ---1.03M | ---230K | ---104K | ---139K | ---557K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 280.32%999K | 2,278.42%3.03M | -94.08%263K | -57.43%14.78M | 122.82%11.03M | -102.37%-554K | 6.71%-139K | -32.50%4.44M | 300.09%34.72M | -37.72%4.95M |
| Net cash flow | ||||||||||
| Beginning cash position | -93.47%519K | -87.22%1.82M | -72.19%5.56M | 128.88%19.99M | -83.26%3.13M | 94.33%7.95M | 29.80%14.24M | 128.88%19.99M | -58.21%8.73M | 201.37%18.72M |
| Current changes in cash | 100.33%16K | 79.32%-1.3M | 34.91%-3.74M | -228.19%-14.43M | 91.78%2.43M | -132.94%-4.82M | 8.58%-6.29M | -356.43%-5.74M | 192.51%11.25M | -49.80%1.27M |
| End cash Position | -82.92%535K | -93.47%519K | -87.22%1.82M | -72.19%5.56M | -72.19%5.56M | -83.26%3.13M | 94.33%7.95M | 29.80%14.24M | 128.88%19.99M | 128.88%19.99M |
| Free cash flow | 76.95%-983K | 29.39%-4.34M | 60.71%-4M | -24.47%-29.21M | -133.48%-8.61M | 51.02%-4.27M | 8.62%-6.15M | -134.62%-10.19M | -12.58%-23.47M | 32.11%-3.69M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg